Ashok Thulluru

Ashok Thulluru

Auto-generated profile, based on publicly available information

Ashok Thulluru

Department of Pharmaceutics, D.Y. Patil Education Society, Kolhapur, Maharashtra India

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2026 in Recent Advances in Drug Delivery and Formulation
Verified
Journal Article
Closed access
PDF file
ATAshok Thulluru
Ashok Thulluru
CJChandraprabhu Jangme
Chandraprabhu Jangme
VPVrushabh Patil
Vrushabh Patil
Introduction/ Objective: Rheumatoid Arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the synovial joints, leading to joint destruction and systemic complications. Existing therapies, such as Disease-Modifying Antirheumatic Drugs (DMARDs) and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), are typically associated with low efficiency, systemic side effects, and poor patient compliance. Methods: A literature search was conducted using PubMed, Google Scholar, ScienceDirect, and Web of Science to identify relevant studies published between 2005 and 2025. The search employed the keywords "rheumatoid arthritis," "cubosomes," "cubosomal gel," "nanocarriers," and "targeted drug delivery" with Boolean operators (AND/OR). English-language studies focusing on cubosome-based drug delivery for rheumatoid arthritis were included, while non-English publications, duplicates, and unrelated studies were excluded. The selected literature was qualitatively synthesized to summarize current advances and therapeutic potential. Results: Preclinical research demonstrates that cubosomal gels enhance Pharmacodynamic effects, improve drug retention in inflamed joints, and reduce systemic toxicity. Such systems show improved bioavailability and therapeutic action compared to traditional therapies. Nonetheless, issues such as scale-up manufacturing, stability, and regulatory acceptance remain. Discussions: Cubosomal gels would be an effective platform for safer, more effective, and personalized RA therapies. New studies are advised on stimuli-responsive systems and multifunctional targeting to maximize clinical responses and translate them into patient care. Conclusion: Nanocarrier-based drug delivery systems offer enhanced targeted delivery and controlled release. Cubosomes, lipid-based nanostructures with bicontinuous cubic phases, effectively encapsulate both hydrophilic and hydrophobic drugs. This study demonstrates that cubosomes significantly improve topical RA treatment when incorporated into gel formulations, enhancing skin penetration, bioadhesion, and localized drug delivery. These findings have important clinical implications, suggesting cubosomes may reduce systemic side effects while maximizing therapeutic efficacy at diseased sites.

7 October 2026 in Drug Delivery Letters
Verified
Journal Article
Closed access
PDF file
ATAshok Thulluru
Ashok Thulluru
CJChandraprabhu Jangme
Chandraprabhu Jangme
RVRohini Vichare
Rohini Vichare
SDShraddha Dingare Deshpande
Shraddha Dingare Deshpande
VPVrushabh Patil
Vrushabh Patil
Introduction: Obesity affects hundreds of millions of adults worldwide and represents a major risk factor for metabolic disorders, including type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease. Berberine (BBR) and epigallocatechin gallate (EGCG) are bioactive phytochemicals that exhibit anti-obesity effects through multiple mechanisms, including activation of AMP-activated protein kinase (AMPK), inhibition of lipogenesis, stimulation of thermogenesis, and modulation of the gut microbiota. However, their therapeutic applications are limited by poor oral bioavailability due to low aqueous solubility, chemical instability, and extensive first-pass metabolism, which restrict their absorption and biological efficacy. Methods: A comprehensive literature analysis was conducted on novel nanocarrier platforms, including lipid-based systems (liposomes, solid lipid nanoparticles, nanostructured lipid carriers, nanoemulsions), polymeric nanoparticles (PLGA, chitosan, protein-based carriers), inorganic nanocarriers, and molecular complexation strategies for BBR and EGCG delivery in obesity models. Results: Recent studies indicate that nano-formulation strategies can substantially enhance the solubility, stability, absorption, and bioavailability of BBR and EGCG compared with conventional formulations. Different nanocarrier systems demonstrate distinct advantages; however, limitations related to formulation stability, scalability, safety assessment, reproducibility, and regulatory approval remain major barriers to clinical application. Preclinical studies suggest that nano-delivered BBR and EGCG may improve metabolic outcomes, including reductions in body weight gain, adiposity, inflammation, and hepatic lipid accumulation, although further validation in well-designed clinical studies is required. Discussion: This review systematically evaluates advanced nano-delivery systems designed to overcome bioavailability barriers of BBR and EGCG, focusing on pharmacokinetic enhancement, targeted delivery, and improved anti-obesity efficacy across preclinical models to inform clinical translation strategies. Conclusion: Nanomedicine-based delivery platforms represent a promising strategy to unlock the anti-obesity therapeutic potential of BBR and EGCG. Future research should focus on the co-delivery of Nanoformulations that utilise the complementary anti-obesity effects of BBR and EGCG and evaluate their clinical feasibility.

5 November 2026 in Recent Advances in Drug Delivery and Formulation
Verified
Journal Article
Closed access
PUPratik Ugare
Pratik Ugare
MKMallinath Kalshetti
Mallinath Kalshetti
ATAshok Thulluru
Ashok Thulluru
VPVrushabh Patil
Vrushabh Patil
BPBahubali Patil
Bahubali Patil
Introduction/Objective: Migraine is a prevalent neurological condition characterised by headaches and other related symptoms, which severely impact quality of life due to the failure to deliver drugs to the brain and side effects related to the Blood-Brain Barrier (BBB). Nasal drug delivery is an alternative non-invasive route to the brain, bypassing the BBB. Cubosomes, lipid-based nanocarriers with exclusively cubic phase structures, have attracted interest as nasal delivery vehicles due to their biocompatibility, mucoadhesive properties, and ability to entrap both hydrophilic and hydrophobic drugs. Methods: A systematic literature search was conducted in PubMed, Scopus, and Web of Science for peer-reviewed studies on cubosome-based nasal gels, intranasal delivery, mucoadhesive in situ gels, nose-to-brain delivery, and migraine therapy. Keywords were combined using Boolean operators AND and OR. Records were screened by title, abstract, and full text, with duplicates and irrelevant or non-scholarly sources excluded. Eligible studies were qualitatively synthesized based on formulation approaches, delivery mechanisms, preclinical evidence, limitations, and translational prospects. Results: Cubosome-based nasal formulations exhibit increased brain bioavailability, rapid absorption, and sustained drug delivery, which improve treatment outcomes in migraine models. Integration into in situ gels increases nasal residence time and reduces mucociliary clearance. Preclinical studies report minimal toxicity and good tolerability. Emerging multifunctional systems have the potential to deliver personalised, targeted treatment for migraines. Discussion: Intranasal cubosome delivery systems have strong potential to overcome blood-brain barrier restrictions through nose-to-brain administration. Their cubic nanostructure is distinctive, enhancing drug loading, stability, and controlled release, while in situ gel incorporation increases residence time and mucosal adhesion. Preclinical evidence indicates improved therapeutic efficacy and low systemic toxicity. Nevertheless, additional optimisation and clinical trials are needed to establish long-term safety, scalability, and the feasibility of migraine management. Conclusion: Cubosome-mediated nasal delivery is a powerful and flexible system for braintargeted migraine therapy. To translate these promising systems into clinical practice, it will be essential to address formulation and manufacturing challenges and ensure rigorous clinical validation.

29 September 2026 in Mini-Reviews in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
ATAshok Thulluru
Ashok Thulluru
VPVrushabh Patil
Vrushabh Patil
CJChandrapraphu Jangme
Chandrapraphu Jangme
PCPoonam Chougule
Poonam Chougule
PPPrajakta Pujari
Prajakta Pujari
Introduction: Drug-Induced Liver Injury (DILI) is a leading cause of drug attrition, postmarketing withdrawals, and acute liver failure. It presents a major barrier to the safe development of new therapeutics, particularly due to its unpredictable pathogenesis and the lack of reliable preclinical models. Current diagnostic tools, primarily reliant on liver enzyme elevations, lack specificity and sensitivity, especially in cases of idiosyncratic DILI. With increasing awareness of these limitations, there is growing interest in integrating advanced delivery systems, predictive models, and pharmacogenomic screening into drug safety assessment. Methodology: This review systematically synthesizes peer-reviewed literature identified through Scopus, PubMed, and Web of Science, published over the past two decades. The review focuses on mechanistic insights into Drug-Induced Liver Injury (DILI), diagnostic challenges, and recent advances in nanocarrier-based drug delivery and predictive strategies. Relevant literature was identified using search terms such as “DILI,” “nanocarriers,” “pharmacogenomics,” and “liver toxicity. Results: Recent findings underline the complex etiology of DILI, involving mitochondrial dysfunction, reactive metabolite accumulation, and immune-mediated responses. Nanoparticle-based drug formulations, including liposomes, polymeric nanoparticles, and dendritic systems, demonstrate promise in reducing hepatic exposure and delivering hepatoprotective co-agents. Innovations such as liver-on-a-chip models and AI-driven predictive tools offer enhanced screening potential. Pharmacogenomic profiling is increasingly recognized for enabling individualized risk assessment. Discussion: The integration of nanotechnology with predictive toxicology and pharmacogenomics represents a significant advancement in DILI prevention and early detection. These emerging approaches address many limitations of conventional preclinical models by providing more physiologically relevant systems and supporting personalized therapeutic strategies. However, challenges related to clinical translation, regulatory acceptance, cost, and validation across diverse populations remain to be addressed. Conclusion: Advances in nanocarrier-based drug delivery, pharmacogenomics, and human-relevant predictive models have the potential to transform DILI risk assessment and improve drug safety. Continued interdisciplinary research, large-scale clinical validation, and regulatory integration are essential for translating these innovations into routine pharmaceutical development and clinical practice.